EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The Role of Novel Small Molecule Drugs in the Management of Inflammatory Bowel Disease

Nadia Eden, Elizabeth Gaunt, Elaine Ming San Ong, Kassem Sharif, Christian Selinger

British Journal of Hospital Medicine · 2025

DOI: 10.12968/hmed.2024.0798 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Hospital Medicine, 2025. Verfasst von Nadia Eden und 4 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Inflammatory Bowel Diseases, Colitis, Ulcerative. Die Arbeit nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment algorithms have traditionally been based on biological therapy when conventional therapy was not successful in controlling inflammatory bowel disease (IBD). Novel small molecule drugs (SMDs) for IBD include the Janus Kinase (JAK) inhibitors Tofacitinib, Filgotinib and Upadactinib and the sphingosine-1 phosphate (S1P) inhibitors Ozanimod and Etrasimod. SMDs have advantages over biologics, such as oral administration, lack of immunogenicity, and rapid onset of action. All agents are effective in treating ulcerative colitis, while Upadactinib is the only SMD for Crohn’s disease. There is growing interest in the use of JAK inhibitors for acute severe colitis. However, safety profiles are distinct from biologics. Clinicians need to be aware of the need for additional lipid monitoring for JAK inhibitors. S1P inhibitors require pre-treatment electrocardiograms to reduce the risk of bradycardia and retinal exams at least in high-risk patients to avoid macular oedema. In this review we highlight the key evidence on efficacy and safety for general hospital physicians.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsInflammatory Bowel DiseasesColitis, UlcerativeHumansPiperidinesPyrimidinesPyrrolidinesIndansOxadiazolesPyrrolesCrohn DiseaseHeterocyclic Compounds, 3-RingNitrilesSphingosinePyridinesTriazoles

Stichwörter der Autor:innen

Crohn’s diseaseJAK inhibitorsinflammatory bowel diseasesmall molecule drugsulcerative colitis

Substanzen

Janus Kinase InhibitorstofacitinibPiperidinesozanimodPyrimidinesPyrrolidinesIndansGLPG0634Oxadiazolesupadacitinib

Autor:innen und Institutionen

  • Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Zitieren

APA

Eden, N., Gaunt, E., Ong, E. M. S., Sharif, K., & Selinger, C. (2025). The Role of Novel Small Molecule Drugs in the Management of Inflammatory Bowel Disease. British Journal of Hospital Medicine. https://doi.org/10.12968/hmed.2024.0798

Vancouver

Eden N, Gaunt E, Ong EMS, Sharif K, Selinger C. The Role of Novel Small Molecule Drugs in the Management of Inflammatory Bowel Disease. British Journal of Hospital Medicine. 2025. doi:10.12968/hmed.2024.0798

BibTeX
@article{Eden2025,
  author = {Eden, Nadia and Gaunt, Elizabeth and Ong, Elaine Ming San and Sharif, Kassem and Selinger, Christian},
  title = {The Role of Novel Small Molecule Drugs in the Management of Inflammatory Bowel Disease},
  journal = {British Journal of Hospital Medicine},
  year = {2025},
  doi = {10.12968/hmed.2024.0798}
}
Kostenlos starten →